Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) just days before the drug’s Prescription Drug User Fee Act (PDUFA) date.

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The UK's FTSE 100 extended its winning streak to a fourth week on Friday, as investors looked past economic concerns to focus ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

By Sanchayaita Roy and Twesha Dikshit (Reuters) -European shares were unchanged on Friday, as losses in heavyweight ...

US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company ...